Celldex stock rises after positive phase 3 trial results
Celldex Therapeutics (CLDX) shares rose 8% after reporting positive Phase 3 trial results for barzolvolimab in treating chronic spontaneous urticaria (CSU). Both trials met primary and secondary endpoints, showing significant improvements in disease activity. The 150 mg and 300 mg doses outperformed placebos, with complete response rates of 42.4%-54.0% versus 9.3%-12.6%. The drug was well-tolerated, and Celldex plans an FDA submission in 2027.
How this was made
The 30-second read
Why it matters
The trial data provides a concrete catalyst for valuation re‑rating and may accelerate the BLA filing timeline.
Market read
First‑report of pivotal trial data, driving immediate price movement and setting expectations for regulatory approval.
What to watch
The upcoming 52‑week safety data and competitive pipeline from larger pharma could temper upside.
Background
Celldex Therapeutics (NASDAQ:CLDX) focuses on chronic spontaneous urticaria treatments; the EMBARQ‑CSU trials are its largest late‑stage program.
Ticker impact
Celldex Therapeutics announced positive Phase 3 trial results for barzolvolimab, driving an 8% share rise.
upward pressure, potential 10‑15% rally over the next weeks as investors price in approval expectations.
Phase 3 endpoints were met with statistically significant improvements; the company plans an FDA BLA in 2027, and the market reacted immediately.
Market effects
Strengthens the biotech/dermatology space, may lift peers developing CSU therapies.
Positive for US biotech sector, limited broader market effect.
Highlights continued demand for novel allergy‑related treatments worldwide.
Counterpoint
If regulatory scrutiny intensifies or safety signals emerge in longer‑term data, the rally could reverse.
Key entities
- companyCelldex Therapeutics
Biotech firm developing barzolvolimab for chronic spontaneous urticaria.
